Health Boards
AbGenomics International will regain global rights to AbGn-168H from Boehringer Ingelheim, with effect from 13 February 2012.
The move was made following the termination of collaboration between both the companies.
AbGn-168H, a humanized monoclonal antibody against CD-162 preferentially induces apoptosis of late-stage activated T-cells and is under development to treat psoriasis and other immunological diseases.
AbGenomics intends to carry on with the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and hence will seek a new partner.
AbGenomics founder and CEO Rong- Hwa Lin said the company had a good collaboration agreement with Boehringer Ingelheim since 2005.
"While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug," Hwa Lin added.
Source: pharmaceutical-business-review.com
The move was made following the termination of collaboration between both the companies.
AbGn-168H, a humanized monoclonal antibody against CD-162 preferentially induces apoptosis of late-stage activated T-cells and is under development to treat psoriasis and other immunological diseases.
AbGenomics intends to carry on with the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and hence will seek a new partner.
AbGenomics founder and CEO Rong- Hwa Lin said the company had a good collaboration agreement with Boehringer Ingelheim since 2005.
"While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug," Hwa Lin added.
Source: pharmaceutical-business-review.com
